Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure

To investigate the effects of levosimendan, a positive inotropic agent, on the new heart failure markers immunoglobulin free light chains kappa and lambda (FLC-κ and FLC-λ) in decompensated chronic heart failure (HF), 59 patients with New York Heart Association (NYHA) class III–IV HF were enrolled. Patients were randomized into levosimendan (n = 31) and standard HF treatment (n = 29) groups. Serum FLC-κ and FLC-λ, brain natriuretic peptide (BNP), and ejection fraction (EF) were measured before treatment and on the 5th day of treatment initiation. Forty-two percent of subjects were females (n = 25) and overall mean age was 64.1 ± 10.7 years. FLC-κ (P < 0.05) and FLC-λ (P < 0.05) were significantly decreased in the levosimendan group compared to baseline, but no difference in either marker in the standard treatment group was observed. Pre- and post-treatment FLC-κ/FLC-λ ratios in both groups were similar, whereas FLC-κ and FLC-λ levels and the FLC-κ/FLC-λ ratio showed no significant correlation with NYHA class, brain natriuretic peptide (BNP) and ejection fraction (EF) levels; and BNP and EF changes after the treatment. Symptomatic improvement in the levosimendan group according to the NYHA class was significantly better than in the standard treatment group (P = 0.044). While 55.2% of patients in the levosimendan group showed a 1-degree shift to lower NYHA classes, 10.3% showed a 2-degree decrease. In conclusion, levosimendan caused short-term hemodynamic and symptomatic improvements, with a more pronounced decrease in FLC levels in patients with advanced decompensated HF.     

Nitroimidazole-induced chronic hepatitis

Drug-induced chronic hepatitis is a rare pathological condition. There is no reported case with chronic hepatitis secondary to nitroimidazole use. We report a patient who developed nitroimidazole-induced chronic hepatitis following acute exacerbation of hepatitis three times after nitroimidazole use.     

Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis B

We studied clinical and laboratory effects of 3 months of lamivudine with adefovir combination and adefovir dipivoxil (AD) alone in the treatment of patients with lamivudine-resistant hepatitis B virus (HBV) infection. Eligible patients were hepatitis B surface antigen-positive men and women with compensated liver disease who were given lamivudine at least more than 6 months and had HBV polymerase gene mutation. Patients were assigned to receive adefovir 10 mg/day (Group 1) or adefovir 10 mg once daily and lamivudine 100 mg once daily combination during first 3 months, and then stopped lamivudine and continued adefovir (Group 2). Median age was 48 years (34 males and 20 females, and 35 were HBeAg-negative). Baseline median ALT, AST, and HBV DNA levels were 66 IU/l, 49 IU/l, and 6.7 log₁₀ copy/ml, respectively. Median adefovir therapy time and ALT normalization time were 9 and 3.5 months, respectively. There was no significant difference between groups according to the baseline HBV DNA, ALT, HBe Ag status, age, gender, and lamivudine resistance time. Virological and biochemical responses were similar in both groups during therapy. Two patients (8%) had ALT flare more than five times upper limit of normal without any clinical decompensation in Group 1. Mild ALT elevation according to baseline levels were found in 8 (27.6%) and 4 (17.4%) patients, respectively, in Group 2 and Group 1, and no statistically significance between two groups. In conclusion, this study showed that it is not necessary to continue lamivudine therapy while switching to AD therapy. Adefovir alone is effective in the treatment of patients with lamivudine resistant HBV infection and compensated liver disease, without significant clinical and laboratory flares. However, it is not easy to say that switching to AD with cessation of lamivudine is safe, because the study population is not enough for precise conclusion and resistance may be a considerable problem against AD in patients using long-term treatment.     

Laryngeal actinomycosis accompanying laryngeal carcinoma: report of two cases

Actinomycosis is a systemic chronic bacterial infection caused by Actinomyces israelii, an anaerobic organism normally resident in the human mouth. It can involve any organ, but cervicofacial disease is the most common. Laryngeal involvement is rare and usually occurs secondary to the oral, cervical or mandibular disease. There are only a few cases of primary laryngeal actinomycosis (LA) in the literature. Actinomycosis can also be a complication of head and neck surgery. Here we present two cases of LA accompanying laryngeal carcinoma and discuss in the literature about this event.     

OC12Lipoid proteinosis (Urbach-Wiethe disease)

Lipoid proteinosis (LP), also known as Urbach-Wiethe disease is a rare, autosomal recessive disorder associated with deposition of acid-Schiff (PAS)-positive hyaline-like material in various tissues including skin, mucosal membranes and internal organs. The aetiology of LP is currently unknown. A 17-year-old male complaining of oral lesions and tooth pain was referred to our clinic, depending on characteristic infandible hoarseness, pox-like and acneiform scar-like lesions on his face, beaded eyelid papules, loss of hair, tuberous nodules on the elbows and generalized skin thickening had been diagnosed with LP. He had the characteristic old-looking appearance. Intraoral examination showed macroglossia with a thickened frenulum and lateral impressions of teeth, yellowish papules on the tongue and yellowish deposits on the soft palate. There wasn't any structural abnormalities in radiographic examination. He had no other systemic disorder. He had poor oral hygiene, severe periodontal problems and multiple severe caries lesions. The patient was evaluated for the individual treatment needs of the problems he had been. The teeth extractions, restorative and periodontal treatments were done. Intraoral tissues were fragile, and healing process was observed to be slower than usual. In this case, limited mouth opening, macroglossia and the thickened oral mucosa restricted the treatment procedures in oral region. Throughout medical treatment patient's oral health status will be followed. This report pointed out to the rare finding of gingival hyperplasia due to hyalin-like material deposition in gingival tissues, which was not induced by any drug therapy.     

Meningitis due to Gemella haemolysans in a pediatric case

Gemella haemolysans is a rare pathogen in cases of bacterial meningitis. We present a case of meningitis due to G. haemolysans in a 17-month-old boy. This is the first reported case of Gemella meningitis in a child. The patient completely recovered following intravenous therapy with linezolid and chloramphenicol.     

Discrepancies between Doppler and catheter gradients in ventricular septal defect: a correction of localized gradients from pressure recovery phenomenon

Although very high gradient levels were measured during the evaluation of ventricular septal defect (VSD) in daily practice, these measurements are generally interpreted as erroneous and thus neglected. Our aim was to assess the features of VSD’s having erroneous interventricular pressure gradients by echocardiography. A 46 patients were enrolled in the study. The patients with higher Doppler-derived interventricular gradient than brachial systolic blood pressure were compared with patients with lower gradient (group 1, n = 26; group 2, n = 20, respectively) in terms of echocardiographic characteristics of VSD. No significant relations were observed in systolic and diastolic blood pressure and interventricular synchronicity between two groups (117.1 ± 6.7 vs 110.2 ± 6.3 mmHg, p = 0.145; 74.7 ± 4.3 vs 73.2 ± 4.9 mmHg, p = 0.32; 31.2 ± 5.5 vs 33.2 ± 4.9 msn, p = 0.29, respectively). Left ventricular end-diastolic and end-systolic diameters were greater in group 2 (46.6 ± 3.5 vs 49.5 ± 4.5, p = 0.022; 30.3 ± 2.5 vs 32.9 ± 3.2, p = 0.004, respectively). Doppler-derived interventricular pressure gradients were significantly higher in group 1 (144.4 ± 13.6 vs 75.7 ± 5.1 mmHg, p < 0.001, respectively). Defect width was significantly lower (3.20 ± 0.40 vs 4.8 ± 1.8 mm, respectively, p < 0.05), and length was greater in group 1 patients (5.75 ± 0.90 vs 2.80 ± 0.80 mm, p < 0.05, respectively). There was a significant positive correlation between pressure gradient and defect length (r = 0.84, p < 0.001), and a negative correlation between pressure gradient and defect width (r = ?0.66, p < 0.001). Defect length/width was significantly greater in group 1. With the cut-off value of 1.2, defect length/width was able to predict tunnel-type VSD with sensitivity of 88.5 % and specificity of 72.7 %. Continuous-wave Doppler method may overestimate interventricular pressure gradients in patients with tunnel-type ventricular septal defect.